On June 12, Foundation Medicine (member of the Roche Group), a Massachusetts-based molecular information company providing genomic profiling services that help personalize cancer care, announced that it had completed the acquisition of Lexent Bio, Inc. Wilson Sonsini Goodrich & Rosati advised Lexent Bio in the transaction and has advised Lexent Bio since its formation. The total potential consideration was undisclosed, but included an upfront payment as well as contingent milestone payments.

Lexent Bio is a California-based precision oncology company building novel liquid biopsy technology to advance cancer care. The acquisition will accelerate Foundation Medicine’s research and development strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The technology developed by Lexent Bio complements Foundation Medicine’s existing efforts and partnerships aimed at developing advanced diagnostics for physicians, as well as genomically evaluating disease progression and informing treatment decisions at earlier stages of disease.

The Wilson Sonsini team advising Lexent Bio includes the following attorneys:

Corporate
Mark Solakian, Partner
Jake Gatof, Associate
Amanda Creedon, Associate
Leah Hengemuhle, Associate

Patents and Innovations
Vern Norviel, Partner

Technology Transactions
Lowell Segal, Partner

Employee Benefits & Compensation
Scott McCall, Partner
Michael Klippert, Associate
Jason Chan, Associate

Regulatory
David Hoffmeister, Partner
Eva Yin, Associate

Employment Law
Rico Rosales, Partner
Aren Balabanian, Associate

Privacy and Cybersecurity
Matt Staples, Partner
Daniel Chen, Associate

For more information, please refer to the press release announcing the transaction.